Rein Therapeutics, Inc.NASDAQ: RNTX

Rein Therapeutics to Present at Upcoming September Investor Conferences

· Issued by Rein Therapeutics, Inc. via GlobeNewswire

Summary by 6ix AI

Rein Therapeutics, a biopharmaceutical company developing medicines for rare lung and fibrosis (tissue scarring) conditions, said President and CEO Brian Windsor will present at two investor conferences in New York, NY in September 2026.

Key details

  • 2026 Cantor Global Healthcare Conference: Friday, September 11, 2026, at 8:00 a.m. ET, in New York, NY.
  • H.C. Wainwright 28th Annual Global Investment Conference: Monday, September 14, 2026, at 11:00 a.m. ET, in New York, NY.
  • A live webcast of the presentations will be available in the Investors section of the Rein website at ir.reintx.com, with an archived replay available for approximately 90 days following the conference.

6ix AI wrote this summary from the release below and checked it against the release.

AUSTIN, Texas, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, President and Chief Executive Officer of Rein Therapeutics, will present at the following investor conferences in September.

2026 Cantor Global Healthcare Conference
Date & Time: Friday, September 11, 2026, at 8:00 a.m. ET
Location: New York, NY

H.C. Wainwright 28th Annual Global Investment Conference
Date: Monday, September 14, 2026 at 11:00 a.m. ET
Location: New York, NY

A live webcast of the presentations may be accessed via the Investors section of the Rein website at ir.reintx.com. An archived replay of the events will be available on the website for approximately 90 days following the conference.

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 has received both Orphan Drug and Fast Track designations in the U.S.

Investor Contact

[email protected]

Rein Therapeutics, Inc. on 6ix

Story so far

Earlier from Rein Therapeutics

Later from Rein Therapeutics

All Rein Therapeutics news releases